{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:30:18Z","timestamp":1793867418584,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015083","name":"Peking University People's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDKF2025-10"],"award-info":[{"award-number":["RDKF2025-10"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clml.2026.09.011","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:04:24Z","timestamp":1789502664000},"page":"e1249-e1259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Characteristics and Prognostic Analysis of Pediatric Acute Myeloid Leukemia With CBFB::MYH11: A 10-Year Single-Center Cohort Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0051-2095","authenticated-orcid":false,"given":"Zhi-xiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-ping","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7381-6236","authenticated-orcid":false,"given":"Hui-min","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.clml.2026.09.011_bib0002","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.2024027904","article-title":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel","volume":"147","author":"Zwaan","year":"2026","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.09.011_bib0003","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc840","article-title":"Core-binding factors in haematopoiesis and leukaemia","volume":"2","author":"Speck","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.clml.2026.09.011_bib0004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2026.09.011_bib0005","first-page":"909","article-title":"Expert consensus on the diagnosis and treatment of pediatric acute myeloid leukemia (2024","volume":"62","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"6","key":"10.1016\/j.clml.2026.09.011_bib0006","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2004.07.012","article-title":"Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461","volume":"22","author":"Byrd","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.09.011_bib0007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2026.09.011_bib0008","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","article-title":"Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98","volume":"28","author":"von Neuhoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.09.011_bib0009","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"Borthakur","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.011_bib0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41375-026-02900-x","article-title":"Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia","volume":"40","author":"Vasseur","year":"2026","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2026.09.011_bib0011","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/08880018.2025.2601128","article-title":"Prospective evaluation of KIT mutations and long-term outcomes in pediatric core binding factor acute myeloid leukemia: a single institutional study in China","volume":"43","author":"Hou","year":"2026","journal-title":"Pediatr Hematol Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.09.011_bib0012","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/bloodadvances.2021004965","article-title":"CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes","volume":"5","author":"Huang","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2026.09.011_bib0013","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/ejh.14192","article-title":"Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)\/t(16;16)\/CBFB::MYH11","volume":"112","author":"Gao","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0014","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ped.13440","article-title":"Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia","volume":"60","author":"Matsuo","year":"2018","journal-title":"Pediatr Int"},{"issue":"22","key":"10.1016\/j.clml.2026.09.011_bib0015","doi-asserted-by":"crossref","first-page":"SCI","DOI":"10.1182\/blood.V128.22.SCI-30.SCI-30","article-title":"Molecular minimal residual disease detection in acute myeloid leukemia [abstract]","volume":"128","author":"Valk","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2026.09.011_bib0016","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.09.011_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjh.16745","article-title":"The loss or absence of minimal residual disease of <0\u00b71% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis","volume":"192","author":"Duan","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0018","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-020-07043-5","article-title":"Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment","volume":"20","author":"Hu","year":"2020","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.clml.2026.09.011_bib0019","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-18-1897","article-title":"Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia","volume":"25","author":"Tarlock","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clml.2026.09.011_bib0021","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.bbmt.2017.04.023","article-title":"IFN-\u03b1 is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study","volume":"23","author":"Mo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2026.09.011_bib0022","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00277-021-04432-z","article-title":"Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center","volume":"100","author":"Duan","year":"2021","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2026.09.011_bib0023","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/biomedicines9080953","article-title":"How to improve prognostication in acute myeloid leukemia with CBFB-MYH11 fusion transcript: focus on the role of molecular measurable residual disease (MRD) monitoring","volume":"9","author":"Talami","year":"2021","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.clml.2026.09.011_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26612","article-title":"Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children's Oncology Group","volume":"64","author":"Johnston","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"10.1016\/j.clml.2026.09.011_bib0025","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1182\/blood-2011-07-364661","article-title":"Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16)","volume":"118","author":"Creutzig","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0026","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12885-023-10965-5","article-title":"Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)","volume":"23","author":"Qiu","year":"2023","journal-title":"BMC Cancer"},{"issue":"27","key":"10.1016\/j.clml.2026.09.011_bib0027","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.09.011_bib0028","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hon.3015","article-title":"Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission","volume":"40","author":"Wang","year":"2022","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.09.011_bib0029","doi-asserted-by":"crossref","first-page":"726","DOI":"10.21037\/tp-20-102","article-title":"Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis","volume":"9","author":"Fan","year":"2020","journal-title":"Transl Pediatr"},{"issue":"3","key":"10.1016\/j.clml.2026.09.011_bib0030","first-page":"177","article-title":"Analysis of C-KIT gene mutation in pediatric core-binding factor acute myeloid leukemia","volume":"37","author":"Wu","year":"2019","journal-title":"Lin Chuang Er Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0031","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/16078454.2022.2078027","article-title":"AML with inv(16)\/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome","volume":"27","author":"Assaf","year":"2022","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.clml.2026.09.011_bib0032","article-title":"Clinical characteristics and prognosis of pediatric acute myeloid leukemia with inv(16)\/CBF\u03b2-MYH11 positive","volume":"36","author":"Wu","year":"2018","journal-title":"Lin Chuang Er Ke Za Zhi"},{"issue":"2","key":"10.1016\/j.clml.2026.09.011_bib0033","first-page":"367","article-title":"Clinical characteristics and prognosis of acute myeloid leukemia patients with inv(16)\/t(16;16)(p13.1;q22) and\/or CBF\u03b2-MYH11","volume":"30","author":"Wang","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.clml.2026.09.011_bib0034","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","article-title":"Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)","volume":"121","author":"Paschka","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.09.011_bib0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.09.011_bib0036","first-page":"2281","article-title":"Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemia","volume":"110","author":"Yang","year":"2025","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2026.09.011_bib0037","article-title":"Distinct prognosis and transplant timing in core-binding factor acute myeloid leukemia [abstract]","volume":"146","author":"Huang","year":"2025","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:23:11Z","timestamp":1793866991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2152265026032982"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Characteristics and Prognostic Analysis of Pediatric Acute Myeloid Leukemia With CBFB::MYH11: A 10-Year Single-Center Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}